More research into COVID-19 has shown that 10 per cent of people with diabetes who are admitted to hospital with the virus, die within seven days.
The French Coronavirus SARS-CoV-2 and Diabetes Outcomes (CORONADO) study has also found that nearly a third of hospitalised people with diabetes need ventilation once admitted and old age increases the risk of death.
Diabetes-related complications associated with risk of death after a week was found to be high blood pressure, micro- and macrovascular diabetes-related complications, and comorbidities such as heart failure and treated obstructive sleep apnea.
The findings also indicated body mass index (BMI) is independently associated with death or intubation at seven days, while HbA1c levels, the use of dipeptidyl peptidase–4 inhibitors and renin-angiotensin-aldosterone system (RAAS) blockers were not.
Study co-author Dr Samy Hadjadj, from the Hôpital Guillaume et René Laennec in Nantes, France, said: “Before the CORONADO study it was ‘all diabetes [patients] are the same.’ Now we can surely consider more precisely the risk, taking age, sex, BMI, complications, and [obstructive sleep apnea] as clear ‘very high-risk situations.”
The study involved 1,317 people with diabetes who had been tested for COVID-19 and had been admitted to 53 French hospitals during March 10-31, 2020.
A total of 88.5 per cent had type 2 diabetes, three per cent had type 1 diabetes, and 3.1 per cent had been newly diagnosed on admission. The average age of the participants was 69.8 years. The good news was that there were no deaths among those with type 1 diabetes who were younger than 65.
Dr Hadjadi added that “even in diabetes, each increase in BMI is associated with an increase in the risk of intubation and/or death in the seven days following admission for COVID-19. So, let’s target this population as a really important population to keep social distancing and stay alert on avoiding the virus.”
The researchers were unable to find an association between poor COVID-19 outcomes and medication use.
Dr Hadjadi said: “Insulin is not suspected of having adverse effects closely related to COVID-19. RAAS blockers are not deleterious but indicative of hypertension, which is a comorbidity even in diabetes patients.”
The research findings have been published in the Diabetologia journal.